Email Updates

You are here

AVAC in the News

  • About 1.2 million people in the US are at "substantial risk" of HIV and could benefit from taking a daily pill to prevent the infection, the CDC said.

    November 25, 2015
    MedPage Today
  • A report released by the US CDC finds that roughly 1.2 million people would benefit from PrEP based on their reported rates of otherwise unprotected risk behavior. That’s about 60 times higher than current estimates, which suggest about 21,000 people take the drug.

    November 24, 2015
  • David Kauffman of the New York Post writes how Charlie Sheen’s announcement on being HIV-positive introduced America to the range of treatment options that are already available.

    November 17, 2015
    New York Post
  • In 1984, Dr. Robert Gallo co-discovered HIV as the cause of AIDS, then went on to pioneer the blood test that detects the virus. Now, 31 years later, his team at the University of Maryland School of Medicine's Institute of Human Virology is beginning human trials this month on a potentially revolutionary HIV vaccine.

    October 13, 2015
    HuffPost Science
  • After years of research, a promising HIV/AIDS vaccine at the University of Maryland School of Medicine is moving into the critical human testing stage. The institute's vaccine is just one of about 30 such drugs in some stage of human trials, according to AVAC, an advocacy group devoted to HIV prevention efforts.

    October 9, 2015
    Baltimore Sun
  • Steph Auteri, writing for aasect, links an NYT article on a highly successful IUD promotion campaign in the US to what it will really take to address women’s sexual and reproductive health needs, including commentary on PrEP from IRMA’s Jim Pickett and AVAC’s Mitchell Warren.

    October 6, 2015
  • Everyone with HIV should be offered treatment immediately upon diagnosis, according to new World Health Organization (WHO) guidelines. The recommendation -- dropping any eligibility restrictions for antiretroviral therapy -- brings WHO advice into line with guidelines in the U.S., and most other Western countries.

    October 5, 2015
    MedPage Today
  • The Health Journalists Network in Uganda, dedicated to increasing understanding of health care issues and improving health literacy among Africans, organizes Science Cafés in partnership with AVAC. Science Cafés present a platform for unique public engagement on issues that may be rather isolated from the general public including journalists.

    September 30, 2015
    Africa Science Technology & Innovation News
  • Demonstrating that take a daily pill to prevent HIV infection can work in the real world, San Francisco's largest private health insurer announced Wednesday that not one of its 657 clients receiving the drug had become infected over a period of more than two years.

    September 2, 2015
    NY Times
  • Zimbabwe will start its first HIV vaccine clinical trial as soon as regulatory approvals are achieved. The trial, named HVTN 107, will enroll 24 Zimbabwean participants (of a planned total 132 participants) to test a vaccine similar to the one that reduced risk of HIV infection by 31 percent in the RV144 trial in Thailand. HVTN 107 will also run in South Africa and Mozambique. An overview of AIDS vaccine research can be found here.

    August 30, 2015
    Zim Daily